|Age:||18 years or older|
|Keywords:||colorectal cancer, advanced metastatic colorectal cancer, MCRC, metastatic colorectal cancer, advanced cancer, HER-2, HER-2 amplification|
|Type:||Biological study, Phase 2|
This study has three study groups. Group 1 will receive the study drugs trastuzumab and pertuzumab. The combination of trastuzumab and pertuzumab is investigational (not approved by the FDA for treatment of colorectal cancer). These drugs will be given through a vein on Day 1 of every 21 day cycle. Group 2 will receive the usual chemotherapy, cetuximab and irinotecan, through a vein on Day 1 of every 14 day cycle. If you are in Group 2 and your cancer gets worse, you may have the option to receive the same treatment as Group 1, and be placed into Group 3.
A computer will by chance assign you to treatment groups in the study. This is called randomization. This is done by chance because no one knows if one study group is better or worse than the other.